Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,792.05INR
1 Jun 2015
Change (% chg)

Rs-41.20 (-2.25%)
Prev Close
Rs1,833.25
Open
Rs1,778.00
Day's High
Rs1,815.75
Day's Low
Rs1,771.10
Volume
1,574,696
Avg. Vol
1,976,715
52-wk High
Rs2,115.00
52-wk Low
Rs913.05

LUPN.NS

Chart for LUPN.NS

About

Lupin limited is an India-based transnational pharmaceutical Company, producing a wide range of generic and branded formulations. The Company has market share in key markets in the cardiovascular (prils and statins), diabetology, asthma, pediatrics, CNS, GI, anti-infective and NSAIDs therapy segments, Anti-TB and, cephalosporins... (more)

Overall

Beta: 0.36
Market Cap(Mil.): Rs824,659.81
Shares Outstanding(Mil.): 449.83
Dividend: 7.50
Yield (%): 0.33

Financials

  LUPN.NS Industry Sector
P/E (TTM): 34.38 37.18 39.28
EPS (TTM): 53.33 -- --
ROI: 28.94 16.31 15.64
ROE: 30.41 17.08 16.64
Search Stocks

India's Lupin, Cipla bid for UCB's US generic drugs portfolio - Bloomberg

MUMBAI, June 1 - Indian generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

8:10am EDT

BRIEF-India's BSE to add Lupin to Sensex index, dropping Tata Power

* India's BSE says announces reconstitution of benchmark Sensex index

22 May 2015

BRIEF-Indian drugmaker Lupin to buy Brazil's Medquímica

* Says acquired 100 percent stake in Medquímica Indústria Farmacêutica S.A., Brazil

13 May 2015

Indian shares rise after hitting 1-1/2 month low; defensives lead

MUMBAI, March 24 - Indian shares rose after hitting nearly 1-1/2 month low on Tuesday as investors churned positions in defensive stocks such as Lupin Ltd from pharmaceutical sector on worries the record setting rally has run ahead of fundamentals.

24 Mar 2015

India's Lupin says FDA raises concerns over plant at Pithampur

MUMBAI - The U.S. Food and Drug Administration (FDA) has raised concerns over production processes at a plant that makes oral contraceptives operated by Lupin Ltd, India's fourth-largest generic drug manufacturer by sales.

23 Feb 2015

UPDATE 1-India's Lupin says FDA raises concerns over plant at Pithampur

* Received approval for one drug from plant since FDA audit (Adds plant details, brokerage comment, share move)

23 Feb 2015

Appeals court rules for Lupin, against Teva over generic HIV drugs

- The top U.S. patent appeals court has affirmed a district court decision allowing generic drugmaker Lupin Ltd, but not Teva Pharmaceuticals, to make generic versions of ViiV Healthcare Co's HIV drugs.

12 Feb 2015

UPDATE 2-India extends price caps to 52 more essential drugs

* Regulator says continues work on expanding price control list (Adds comment from Lupin)

12 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$173.00
Provider: Axis Capital Limited
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks